Ascendis Pharma authorizes $400 million share repurchase program
AI Summary- Ascendis Pharma’s Board authorized repurchases of up to $400 million in ordinary shares.
- $400 million is the maximum authorized value, with timing and amounts based on market conditions.
- Ascendis may modify, suspend or terminate the program without notice.